Background Preclinical models recapitulating the metastatic phenotypes are essential for
developing the next‐generation therapies for metastatic prostate cancer (mPC). We aimed to …

Background Novel therapies for men with castration-resistant prostate cancer (CRPC) are
needed, particularly for cancers not driven by androgen receptor (AR) activation. Objectives …

Metastatic disease is a main cause of mortality in prostate cancer and remains to be
incurable despite emerging new treatment agents. Development of novel treatment agents …

Metastatic disease is the principal cause of prostate-cancer-related mortality. Our ability to
accurately recapitulate the spread of prostate cancer to bone—the most common site of …

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …

Developing patient derived models from individual tumors that capture the biological
heterogeneity and mutation landscape in advanced prostate cancer is challenging, but …

Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined,
due to lack of experimental models that mimic different disease stages. We describe an …

Background Constitutively active androgen receptor variants (AR-V) lacking the ligand
binding domain (LBD) may promote the development of castration-resistant prostate cancer …

Cell lines representing the progression of prostate cancer (PC) from an androgen-
dependent to an androgen-independent state are scarce. In this study, we used previously …

BACKGROUND Androgen‐dependent prostate cancer (PrCa) xenograft models are
required to study PrCa biology in the clinically relevant in vivo environment. METHODS …